Alkem Laboratories Ltd

Alkem Laboratories Ltd

Alkem Laboratories Ltd held its 52nd Annual General Meeting (AGM) on August 27, 2026, through video conferencing. The meeting approved all resolutions, including the audited financial statements, interim and final dividend declaration, and re-appointment of directors. The company provided remote e-voting and e-voting facilities to its members.

Alkem Laboratories Ltd

Alkem Laboratories Ltd held its 52nd Annual General Meeting on August 27, 2026, where all resolutions were approved by the members. The meeting was attended by 77 members, and the requisite quorum was present. The company provided remote e-voting and e-voting facilities during the meeting. The resolutions included the adoption of audited financial statements, payment of interim and final dividends, appointment of directors, and ratification of the cost auditor's remuneration.

Alkem Laboratories Ltd

Alkem Laboratories Ltd has made a disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, indicating a potential change in control or substantial acquisition of shares by HDFC Mutual Fund.

Alkem Laboratories Ltd

Alkem Laboratories Ltd has released its Q1 FY27 earnings call transcript, highlighting a 11% year-on-year growth in revenue from operations, with India sales growing 10.3% and international sales growing 16%. The company outperformed the Indian pharmaceutical market in 7 key focus therapies and received 5 ANDAs approval for the U.S. market.

Alkem Laboratories Ltd

Alkem Laboratories Ltd has released its Q1 FY27 earnings call transcript, highlighting a 11% year-on-year growth in revenue from operations, with India sales growing 10.3% and international sales growing 16%. The company outperformed the Indian pharmaceutical market in 7 key focus therapies and received 5 ANDAs approvals for the U.S. market.

Alkem Laboratories Ltd

Alkem Laboratories Ltd held a court-convened meeting on August 17, 2026, to consider the scheme of amalgamation between Alkem Laboratories Limited and Adroit Biomed Limited. The meeting was held through video conferencing, and the results of e-voting showed 99.9999% votes in favour of the scheme.

Alkem Laboratories Ltd

Alkem Laboratories Ltd has published a newspaper advertisement regarding its standalone and consolidated financial results for the quarter ended 30th June, 2026, as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Alkem Laboratories Ltd

Alkem Laboratories Ltd has made the audio recording of its Q1FY27 Earnings Conference Call available on its website, as per SEBI regulations.

Alkem Laboratories Ltd

Alkem Laboratories Ltd has announced the opening of the trading window following the communication of its financial results for the quarter ended 30th June, 2026 to the stock exchanges. The trading window will open on 17th August, 2026.

Alkem Laboratories Ltd

Alkem Laboratories Ltd reported a 10.9% YoY growth in total revenue from operations for Q1FY27, with a 11% revenue growth in Q1FY27. The company outperformed the Indian Pharmaceutical Market (IPM) in seven key focused therapies. The EBITDA margin was 20.5%, a growth of 3.7% YoY. The net profit (after Non-Controlling interest) was ₹5,200 million, with a YoY de-growth of 21.7%. The company has outperformed IPM in seven key focused therapies: Anti-infectives grew by ~1.1X; Gastro-intestinal grew by ~1.2X, VMN ~1.4X, Pain ~1.8X, Anti-Diabetic ~1.4X, Respiratory ~1.6X and Derma ~1.6X.

Alkem Laboratories Ltd

Alkem Laboratories Ltd has informed that its Board of Directors has approved setting up of a new block within the existing manufacturing facility located at Baddi, Himachal Pradesh, and an investment of up to INR 75 crores.

Alkem Laboratories Ltd

Alkem Laboratories Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with a net loss after tax and total comprehensive income. The results were approved by the Board of Directors on August 14, 2026, and are available on the company's website.

Alkem Laboratories Ltd

Alkem Laboratories Ltd has announced the outcome of its Board meeting held on 14th August, 2026, where the Board approved the standalone and consolidated unaudited financial results for the quarter ended 30th June, 2026. The results are available on the company's website.

Alkem Laboratories Ltd

Alkem Laboratories Ltd has received an Official Action Indicated (OAI) status from the US FDA for its manufacturing facility at Amaliya, Daman, following a recent inspection. The facility had received seven observations in a Form FDA 483. The company continues to supply approved products to the US market and will work with the regulator to achieve full compliance.

Alkem Laboratories Ltd

Alkem Laboratories Ltd has appointed Mr. Rajpal Singh Rana as a senior management personnel, effective from August 3, 2026.

Alkem Laboratories Ltd

Alkem Laboratories Ltd has dispatched letters to shareholders providing the web-link to access the Annual Report for FY 2025-26, as per Regulation 36(1)(b) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Alkem Laboratories Ltd

Alkem Laboratories Ltd announced the dispatch of notice of its 52nd Annual General Meeting (AGM) along with the annual report for the financial year 2025-26. The company also published its unaudited quarterly financial results for the quarter ended June 30, 2026, which showed a total income from operations of Rs. 3,444.70 crore and a net profit for the period of Rs. 581.95 crore.

Alkem Laboratories Ltd

Alkem Laboratories Ltd has announced the Notice of 52nd Annual General Meeting (AGM) and Annual Report for FY 2025-2026. The AGM will be held on August 27, 2026, through Video Conferencing (VC)/ Other Audio-Visual Means (OAVM). The Annual Report highlights the company's growth journey, innovation, and diversification into new healthcare opportunities.

Alkem Laboratories Ltd

Alkem Laboratories Ltd has submitted its Business Responsibility and Sustainability Report for the financial year ended 31st March, 2026, as required by SEBI regulations.

Alkem Laboratories Ltd

Alkem Laboratories Ltd has announced the notice of its 52nd Annual General Meeting (AGM) scheduled for August 27, 2026, along with its annual report for the financial year 2025-2026.